PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q95277

Jinichiro KOGA, et al.

Appln. No.: 10/581,717 Group Art Unit: 1652

Confirmation No.: 3601 Examiner: Christian L. Fronda

Filed: June 5, 2006

For: ENDOGLUCANASE STCE AND CELLULASE PREPARATION CONTAINING THE

SAME

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This responds to the Restriction Requirement, dated October 18, 2007. In response to the Restriction Requirement, Applicants elects Group I, claims 1-6 and 16-18 for examination. This election is made with traverse.

The present application is not a U.S. national application, but is a national stage application derived from an international (PCT) application. Therefore, the present application is subject to unity of invention practice pursuant to 37 C.F.R. §§1.475 and 1.499.

According to the International Search and Preliminary Examination Guidelines (available from http://www.wipo.int/pct/en/texts/gdlines.htm), protein X, and a DNA encoding the protein X share a corresponding technical feature, and thus, the protein X and the DNA have unity of

RESPONSE TO RESTRICTION REQUIREMENT

U.S. Application No.: 10/581,717

invention (see Chapter 10 Unity of Invention, 10.59 Example 39). In addition, unity of invention

was not denied in the Written Opinion of the International Search Authority.

Applicants reserve the right to file a Divisional Application directed to non-elected

claims 7-15 and 19-28.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 59,392

/Tu. A. Phan/

Tu A. Phan, Ph.D.

Attorney Docket No.: Q95277

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373

CUSTOMER NUMBER

Date: November 15, 2007

2